OncoHost Selected to Present in Oral Minisymposium at AACR
OncoHost to Present Proteomics-Based Predictive Biomarker
BINYAMINA, Israel, May 25, 2023 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that it will give a poster presentation demonstrating the accuracy of its PROphet® biomarker model at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago, Illinois.
BINYAMINA, Israel , Jan. 11, 2023 /PRNewswire/ -- OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, today announced that its PROphet® platform has been named a winner in the healthcare category of the 2023 BIG Innovation Awards presented by the Business Intelligence Group.
BINYAMINA, Israel , Nov. 7, 2022 /PRNewswire/ -- OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, has developed a novel predictive model for clinical benefit of immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients. The model is based on proteomic profiling of pre-treatment blood samples, combined with machine learning analysis that accurately predicts clinical benefit probability at twelve months, outperforming the predictive capabilities of the existing PD-L1 biomarker. The study was conducted using OncoHost's first-of-its-kind PROphet® platform, and will be presented as a poster at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting.
OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, today announced a peer-reviewed article...
SomaLogic Inc. (Nasdaq: SLGC), a Boulder-based biotechnology company, has licensed its SomaScan protein-diagnostics platform to Israeli life-sciences firm OncoHost Inc.
BINYAMINA, Israel, May 10, 2022 /PRNewswire/ -- OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, today announced the completion of a $35 million Series C funding round. The funding will go towards expanding OncoHost's ongoing multicenter PROPHETIC trial which utilizes PROphet®, the company's machine learning-based host response profiling platform, and supporting the imminent U.S. commercial launch of the precision oncology diagnostic solution.
BINYAMINA, Israel, April 5, 2022 /PRNewswire/ -- OncoHost,?a global leader in?next-generation precision oncology?for improved personalized cancer therapy, announced today that Roswell Park Comprehensive Cancer Center has joined its PROPHETIC study, launching a clinical site in Buffalo, New York.